目的:抗肿瘤免疫治疗的出现对肿瘤患者有益,但更应注意化学免疫疗法的毒副作用。在这里,我们描述了患有NK/T细胞淋巴瘤的患者,该患者在使用由sintilimab联合pegaspargase组成的方案治疗期间出现了中毒性表皮坏死松解症(TEN)。吉西他滨和奥沙利铂(P-GemOx)。病例介绍:1例患者接受6个周期的P-GemOx化疗作为一线治疗;1年后,由于NK/T细胞淋巴瘤复发,他接受了与化学免疫疗法相同剂量的P-GemOx联合sintilimab.他出现了大面积皮疹,在第四次化学免疫疗法后迅速发展为TEN。结论:虽然罕见,据报道,单药PD-1抑制剂或吉西他滨导致致命性TEN的病例.当这两种药物联合使用时,需要仔细注意药物相关的皮肤毒性。该报告强调了TEN作为化学免疫疗法引起的快速和严重不良事件的重要性。
阻断PD-1与其配体相互作用的免疫检查点抑制剂,PD-L1已越来越多地用于癌症治疗。然而,这些药物引起的一些罕见的副作用,如毒性表皮坏死松解症(TEN),可能非常危险。在这里,我们描述了一名患有自然杀伤/T细胞淋巴瘤的患者,该患者在使用sintilimab和pegaspargase/吉西他滨/奥沙利铂(P-GemOx)的组合治疗期间发展为TEN。患者接受6个周期的P-GemOx化疗作为一线治疗,治疗期间或治疗后无皮肤反应。然而,一年后,患者接受相同剂量的P-GemOx联合sintilimab作为复发性自然杀伤/T细胞淋巴瘤的二线治疗,并出现大面积皮疹,经过4个周期的化学免疫疗法后迅速发展为TEN.皮肤毒性是一些最常见的免疫相关不良事件,同时使用抗PD-1和抗PD-L1药物,对应于一类效应。
Aim: The emergence of antitumor immunotherapy has been beneficial for patients with tumors, but more attention should be paid to the toxic side effects of chemoimmunotherapy. Here we describe a patient with NK/T-cell lymphoma who developed toxic epidermal
necrolysis (TEN) during treatment with a regimen consisting of sintilimab combined with pegaspargase, gemcitabine and oxaliplatin (P-GemOx). Case presentation: A patient received six cycles of P-GemOx chemotherapy as first-line treatment; 1 year later, he received the same dose of P-GemOx combined with sintilimab as chemoimmunotherapy due to recurrence of NK/T-cell lymphoma. He developed a massive rash that quickly developed into TEN after the fourth chemoimmunotherapy. Conclusion: Although rare, cases of fatal TEN caused by single-agent PD-1 inhibitor or gemcitabine have been reported. Careful attention to drug-related cutaneous toxicities is needed when these two agents are combined. This report highlights the significance of TEN as a rapid and serious adverse event induced by chemoimmunotherapy.
Immune checkpoint inhibitors that block the interaction of PD-1 with its ligand, PD-L1, have been increasingly used in cancer therapy. However, some rare side effects induced by these drugs, such as toxic epidermal
necrolysis (TEN), can be extremely dangerous. Here we describe a patient with natural killer/T-cell lymphoma who developed TEN during treatment with a combination of sintilimab and pegaspargase/gemcitabine/oxaliplatin (P-GemOx). The patient received six cycles of P-GemOx chemotherapy as first-line treatment and showed no skin reactions during or after treatment. However, 1 year later, the patient received the same dose of P-GemOx combined with sintilimab as second-line treatment for recurrent natural killer/T-cell lymphoma and developed a massive rash that quickly developed into TEN after four cycles of chemoimmunotherapy. Cutaneous toxicities are some of the most prevalent immune-related adverse events, both with anti-PD-1 and anti-PD-L1 agents, which correspond to a class effect.